Alector Reports Q2 2026 Financial Results, Collaboration Revenue Declines to $3.3 Million

Alector, Inc. reported its financial results for the second quarter of 2026, revealing a collaboration revenue of $3.3 million, a significant decrease from $7.9 million in the same period last year. For the first half of 2026, collaboration revenue totaled $4.4 million, down from $11.5 million in the first half of 2025. The decline in revenue is attributed primarily to reduced revenue recognized from the AL101 Alzheimer’s disease program, which has faced setbacks, including the discontinuation of the PROGRESS-AD Phase 2 trial in April 2026.

The company’s operating expenses for the second quarter were $27.7 million, down from $42.0 million in the prior year, reflecting a decrease in both research and development expenses, which fell to $19.5 million from $27.6 million, and general and administrative expenses, which decreased to $8.3 million from $14.4 million. This reduction in expenses is largely due to workforce reductions implemented in previous years, which have allowed Alector to align its resources with its strategic priorities. The net loss for the quarter was $23.0 million, an improvement compared to a net loss of $30.5 million in the same quarter of 2025.

Alector's total assets as of June 30, 2026, were reported at $202.9 million, a decrease from $293.2 million at the end of 2025. The company’s cash and cash equivalents stood at $59.9 million, down from $65.8 million at the end of the previous year. The accumulated deficit increased to $1.018 billion, reflecting ongoing investments in research and development without any product revenue to date. The company has indicated that it expects to continue incurring net losses as it advances its product candidates through clinical trials.

Strategically, Alector has faced challenges with its collaboration agreements, particularly with GlaxoSmithKline (GSK), which terminated its collaboration on the development of certain product candidates, including nivisnebart and latozinemab. This termination, effective January 2, 2027, followed disappointing results from clinical trials. Alector is now focusing on its proprietary Alector Brain Carrier (ABC) platform, which aims to enhance the delivery of therapeutics for neurodegenerative diseases. The company plans to advance its AL137 program for Alzheimer’s disease and its AL050 program for Parkinson’s disease, with IND applications targeted for submission in early 2027.

Looking ahead, Alector anticipates that its existing cash, cash equivalents, and marketable securities will provide sufficient runway to fund operations through at least 2027. However, the company acknowledges the need for additional capital to support ongoing research and development activities. Alector's future financial performance will depend on its ability to successfully navigate the complexities of drug development, secure regulatory approvals, and ultimately commercialize its product candidates.